The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which includes indications like IgAN, Multiple Sclerosis, Immune Thrombocytopenia, SLE, IgG4-RD, wAIHA, NMOSD, Lupus Nephritis, ANCA Vasculitis, CSU, and…
